Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002031636 | SCV002312458 | uncertain significance | DICER1-related tumor predisposition | 2023-06-29 | criteria provided, single submitter | clinical testing | Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt DICER1 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. ClinVar contains an entry for this variant (Variation ID: 1524330). This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 509 of the DICER1 protein (p.Arg509Gln). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with DICER1-related conditions. |
Ambry Genetics | RCV002391142 | SCV002705163 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-07-08 | criteria provided, single submitter | clinical testing | The p.R509Q variant (also known as c.1526G>A), located in coding exon 9 of the DICER1 gene, results from a G to A substitution at nucleotide position 1526. The arginine at codon 509 is replaced by glutamine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005008443 | SCV005637583 | uncertain significance | Euthyroid goiter; Rhabdomyosarcoma, embryonal, 2; Pleuropulmonary blastoma; Global developmental delay - lung cysts - overgrowth - Wilms tumor syndrome | 2024-03-07 | criteria provided, single submitter | clinical testing |